权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Biomarkers of therapeutic response in myotonic dystrophy

强直性肌营养不良治疗反应的生物标志物

基本信息

批准号：
9098817
负责人：
CHARLES A THORNTON
金额：
$ 19.19万
依托单位：
UNIVERSITY OF ROCHESTER
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-07-01 至 2018-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9098817
关键词：
Alternative Splicing Antisense Oligonucleotides Biological Assay Biological Markers Biopsy Biopsy Specimen Capillary Electrophoresis Characteristics Clinical Research Clinical Trials Couples Data Data Set Decision Making Defect Development Disease Dose Event Genetic Goals Health High-Throughput Nucleotide Sequencing Laboratories Lesion Measurement Measures Messenger RNA Methods Muscle Muscle Fibers Muscle Weakness Muscular Dystrophies Mutation Myotonic Dystrophy Pathogenesis Patients Performance Pharmaceutical Preparations Phase Procedures Qualifying RNA RNA Splicing RNA-Directed DNA Polymerase Regulation Reporting Reverse Transcriptase Polymerase Chain Reaction Role Running Sampling Severities Severity of illness Single Nucleotide Polymorphism Staging Systematic Bias Testing Therapeutic Therapeutic Trials Tissue Sample Toxic effect Transcript Work analytical method base clinical practice cohort experience functional disability functional improvement gain of function gel electrophoresis knock-down minimally invasive mouse model mutant next generation sequencing novel small molecule success targeted sequencing targeted treatment therapeutic target therapy design tibialis anterior muscle tissue biomarkers tool transcriptome sequencing treatment response uptake

项目摘要

DESCRIPTION (provided by applicant): Myotonic dystrophy type 1 (DM1) differs from other forms of muscular dystrophy in having an unconventional mutation and a novel disease mechanism. The genetic lesion is an expanded CTG repeat in DMPK, and the mechanism involves a toxic gain-of-function by transcripts containing an expanded CUG repeat (CUGexp). Recent studies have suggested that these unique characteristics create a major therapeutic opportunity. In rapid succession, therapeutic targets responsible for RNA toxicity were identified, agents acting on targets were developed, and reversal of the disease, at least in its early stages, was accomplished in mouse models. As new putative therapies advance to clinical trials, there is a need to obtain conclusive evidence for or against target engagement, at the earliest possible moment, using biomarkers of therapeutic response. The goal of this proposal is to develop assays and biomarkers for this purpose. Major emphasis is placed on alternative splicing because previous work has suggested that splicing misregulation is the best overall readout for downstream effects of RNA toxicity. In addition, analytical methods to assess splicing regulation are very precise, and studies of targeted therapy in mouse models have shown that splicing defects are fully reversible and closely aligned with functional improvement. Building on these observations, and a comprehensive ascertainment of DM1-associated splicing defects from several large data sets, we propose in Aim 1 to develop Multiplex Alternative Splice sequencing (MASseq), a targeted high-throughput sequencing method to assess splicing biomarkers in small muscle biopsy samples. In an effort to qualify MASseq for biomarker analysis, we will optimize the method and then systematically examine sampling variance, assay variance within and between runs, and test-retest reliability. The latter studies will use paired muscle samples from the same subjects, collected eight weeks apart. To test fidelity and assess bias, MASseq results will be compared to reference data from conventional RNAseq of the same samples. Finally, associations of MASseq with functional impairment will be examined. While splicing biomarkers are applicable across all therapeutic strategies for DM1, our second Aim is specifically designed for treatments that reduce cellular levels of toxic RNA. We will develop methods to quantify allelic expression of DMPK, by determining the ratio of mutant versus wild-type transcripts. We will also optimize a novel method to measure the total cellular burden of CUGexp RNA. The results of this project will provide useful biomarkers to guide decision making in clinical trials and potentially in clinical practice, using methods that ae readily transferable to other laboratories.